Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Fruquintinib administered at 5mg once daily in 4 weeks treatment cycle (three weeks on and
one week off) was well tolerated and demonstrated encouraging preliminary clinical antitumor
activity in patients with advanced Colorectal Cancer (CRC) in Phase Ib study.
This study is aimed to evaluate the efficacy and safety of Fruquintinib in the treatment of
patients with metastatic CRC who have progressed after metastatic CRC second line or above
standard chemotherapy.